Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tg100-115. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG known ✓ | P48736 | 13/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | PDXK | O00764 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | PIP5K1C | O60331 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | OXSR1 | O95747 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tg100-115 SCHEMBL29506727 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL31238338 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29361550 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL360279 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29411790 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3539255 | 0.98 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3537211 | 0.98 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3539251 | 0.98 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| SCHEMBL13403357 | 0.92 | PIK3CG (0.85) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3743017 | 0.91 | PIK3CG (0.82) | PIK3CGPIK3CAPIK3CBMTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709382-A1 | METHODS OF TREATING SQUAMOUS CELL CARCINOMA WITH A FARNESYLTRANSFERASE INHIBITOR AND A PI3K INHIBITOR | Kura Oncology, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024233539-A1 | METHODS OF TREATING SQUAMOUS CELL CARCINOMA WITH A FARNESYLTRANSFERASE INHIBITOR AND A PI3K INHIBITOR | KURA ONCOLOGY, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| CN-118930560-A | Bifunctional degradation agents for hematopoietic progenitor cell kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-11-12 | — | — | CN | claimed |
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| CN-118510786-A | Bifunctional degradation agents for hematopoietic progenitor cell kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-115605488-B | Bifunctional degradation agents for hematopoietic progenitor cell kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-08-09 | — | — | CN | claimed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | claimed |
| CN-113227089-B | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2024-07-05 | — | — | CN | claimed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| US-20230035422-A1 | METHODS FOR TREATING DISEASES BY TARGETING ONCOGENIC LIPIDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-02-02 | — | — | US | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| US-20220249609-A1 | COMBINATION THERAPY WITH CD13-TARGETED CHIMERIC PROTEINS OR CHIMERIC PROTEIN COMPLEXES | UNIVERSITEIT GENT (BE) | 2022-08-11 | — | — | US | claimed |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | GILEAD SCIENCES, INC. | 2022-08-04 | — | — | US | claimed |
| WO-2022155495-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-21 | — | — | WO | claimed |
| WO-2022125784-A1 | ENHANCED NANOPARTICLE DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2022076517-A1 | SUBJECT-SPECIFIC TREATMENTS FOR VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-04-14 | — | — | WO | claimed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241281-A1 | Imidazopyrimidine Derivatives | DPYD, KRAS, ABL1 | PIK3CG 433/4885PIK3CD 154/4885PIK3CA 81/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PIK3CG 3569/4885PIK3CD 2996/4885PIK3CA 2438/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | PIK3CG 3429/4885PIK3CD 2727/4885PIK3CA 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.